Skip to main content
HR 4482 115th Congress House Crime and Law Enforcement Administrative law and regulatory procedures Congressional oversight Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Government information and archives Government studies and investigations Health care coverage and access Health information and medical records Health personnel Health programs administration and funding Licensing and registrations Prescription drugs State and local government operations

Opioid Abuse Deterrence, Research, and Recovery Act of 2017

Introduced: November 29, 2017 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 9, 2018
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Dec 1, 2017
Referred to the Subcommittee on Health.
Nov 29, 2017
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Nov 29, 2017
Introduced in House
 Plain-English summary Congressional Research Service

Opioid Abuse Deterrence, Research, and Recovery Act of 2017

This bill amends the Controlled Substances Act to prohibit the Drug Enforcement Administration from registering, or renewing the registration of, a practitioner who is licensed to prescribe opioids in schedule II or III unless the practitioner agrees to limit an opioid prescription for the initial treatment of acute pain to the lesser of a seven-day supply (no refill) or an opioid prescription limit established under state law.

Certain opioid prescriptions are not subject to the limit (e.g., an opioid that is approved and prescribed for the treatment of an opioid use disorder).

The Food and Drug Administration (FDA) must continue to work with stakeholders to promote the development of abuse-deterrent opioid formulations.

The bill requires: (1) the Government Accountability Office to study and report on health care policy changes that may have contributed to the increase in opioid overdoses and deaths, and (2) the FDA to study the feasibility of replacing opioid prescribing limits established by this bill with evidence-based clinical guidelines for opioid prescribing.

What's happening now January 9, 2018

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Republican 1